Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:05:57.697Z.
Calculation as of: 2026-10-06T17:05:57.697Z.
Quote observation: 2026-10-06T17:01:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe921af54d6420969180622b7fbdd7ef934f73e64ffcc47ddb287d73eacb5931
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$11.12M
EV/EBITDA Ratio
N/A
TTM Avg
12.81x
3Y Avg
12.81x
5Y Avg
12.81x
Market Cap
$11.24M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.61M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioVie Inc. (BIVI) | $11.12M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.12M | N/A | 12.81x | 12.81x | 12.81x |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.24M | N/A | N/A | N/A | N/A |
| Pluri Inc. (PLUR)vs › | $11.27M | N/A | 1080.85x | 1080.85x | 1080.85x |
| Caring Brands, Inc. (CABR)vs › | $10.96M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.88M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.39M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.61M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.55M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
